Letter to the Editor

With interest we read the article by Huang et al. about two siblings carrying both the same compound heterozygous *SUCLA2* mutation, which manifested phenotypically with a progressive multisystem syndrome, resulting in severe disability (patient-1) or death (patient-2) [@bb0005]. We have the following comments and concerns.

Patient-1 was treated with dichloroacetate (DCA) over at least 4y. DCA is well-known for its neurotoxicity in MELAS patients, resulting in severe polyneuropathy [@bb0010]. To which degree was the continuous deterioration of the phenotype attributable to the mitochondrion-toxic effect of DCA? Was polyneuropathy by age 1y attributed to the *SUCLA2* mutation or interpreted as side effect of DCA? Was polyneuropathy a complication of diabetes?

Ketogenic diet has been shown to be highly beneficial for epilepsy, migraine, autism, or myopathy in single patients with a mitochondrial disorder (MID) [@bb0015]. Ketogenic diet may even improve cerebral lesions on MRI in Leigh syndrome [@bb0020]. Why was a ketogenic diet not applied to patient-1 but only to patient-2? Was ketogenic diet in patient-2 beneficial?

Patient-1 had normal cerebral MRI at age 3m and callosal thinning at age 7m. Why was no further MRI carried out during the next 13y despite obvious progression of cerebral involvement ([Table 1](#t0005){ref-type="table"})?

Were bone fractures in both patients spontaneous or traumatic? Was a densitometry carried out? Which were the calcium, phosphate, and hormone levels in both patients? Was multiple hormone deficiency attributed to hypopituitarism? Was there a pituitary adenoma?

MID patients frequently develop cardiac disease, which may be subclinical at onset [@bb0025]. Which were the results of long-term ECG and echocardiography when actively searching for cardiac involvement?

Overall, this interesting study could be strengthened by reporting why DCA was given for 4y (patient-1), why no ketogenic diet was tried (patient-1), if there was a pituitary adenoma, and how cerebral involvement progressed on MRI (patient-1).
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Phenotypic manifestations of SUCLA2 mutations in the present and previous studies.

Table 1

  Phenotype                               Patient 1   Patient 2   Previously reported
  --------------------------------------- ----------- ----------- ------------------------------------
  CNS involvement                                                 
   Encephalopathy                         Yes         Yes         \[Lamperti 2012\]
   Dystonia                               Yes         Yes         \[Carrozza 2016\]
   Spasticity                             Yes         Yes         \[Carrozza 2016\]
   Choreoathetosis                        Yes         No          \[Ostergaard 2007\]
   Migraine                               Yes         No          No
   Developmental delay                    Yes         Yes         \[Carrozza 2016\]
   Irritability                           Yes         No          \[Lamperti 2012\]
   Hypotonia                              Yes         Yes         \[Carrozza 2016\]
   Perturbed sleep/wake cycle             No          Yes         No
   Dysarthria/anarthria                   Yes         Yes         \[Lamperti 2012\]
   Basal ganglia involvement              Yes         No          \[Carrozzo 2016, Liu 2014\]
   Epilepsy                               No          No          \[Carrozza 2016\]
   Corpus callosum thinning               Yes         No          No
   Low-lying conus medullaris             No          Yes         No
   Leigh-like MRI                         No          Yes         \[Wortmann 2009\]
  Ocular involvement                                              
   Blindness (optic atrophy)              No          Yes         No
  Otologic involvement                                            
   Hearing loss                           Yes         Yes         \[Morawa 2009, Carrozza 2016\]
  Gastrointestinal involvement                                    
   Cyclic vomiting                        Yes         Yes         \[Carrozza 2016\]
   Constipation                           No          Yes         No
   Gastroparesis                          No          Yes         No
   Gastro-intestinal dysmotility          No          Yes         \[Lamperti 2012\]
   Cecal volvulus                         No          Yes         No
   GERD                                   Yes         Yes         \[Carrozza 2016\]
   Poor feeding                           Yes         Yes         \[Carrozza 2016\]
   Gallstones                             No          Yes         No
  Endocrine involvement                                           
   Diabetes                               Yes         No          No
   Short stature                          Yes         Yes         \[Carrozza 2016\]
   Hypogonadism                           Yes         No          No
   Osteoporosis (spontaneous fractures)   Yes         Yes         No
   Hyperhidrosis                          No          No          \[Carrozza 2016, Ostergaard 2007\]
  Peripheral nerve involvement                                    
   Polyneuropathy                         Yes         Yes         \[Carrozza 2007\]
  Muscle involvement                                              
   Myopathy                               Yes         Yes         \[Carrozza 2016\]
   Ptosis                                 Yes         Yes         \[Carrozza 2016\]
   Facial weakness                        Yes         Yes         \[Liu 2014\]
   Ophthalmoparesis                       Yes         Yes         \[Carrozzas 2016\]
  Bone marrow involvement                                         
   Anemia                                 No          Yes         No
   Thrombocytopenia                       No          Yes         No
  Pulmonary involvement                                           
   Chronic reactive airway disease        Yes         No          \[Carrozzas 2016\]
  Others                                                          
   Cardiomyopathy                         No          No          \[Carrozzo 2007\]
   Sacral dimple                          No          Yes         No
   Immunodeficiency                       No          Yes         \[Carrozza 2016\]
   Dysmorphism                            No          No          \[Carrozza 2016\]
   Fanconi syndrome                       No          No          \[Carrozza 2007\]
   Lactic acidosis                        Yes         Yes         \[Liu 2014\]
   Methylmalonic academia (UOA)           Yes         Yes         \[Liu 2014\]

GERD: gastro-enterological reflux disease, UOA: urine organic acids.
